Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.34 | N/A | -14.97% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.34 | N/A | -14.97% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over current performance but remains focused on long-term goals. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced this quarter.
They emphasized ongoing efforts to improve operational efficiency.
Future product developments were highlighted as a focus.
Biocryst Pharmaceuticals reported a loss per share that was worse than expected, which typically raises concerns among investors. However, the stock rose by 4.58%, likely due to positive sentiment around future product developments and management's commitment to improving operations. Investors may be looking past the current losses in anticipation of better performance ahead.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARRIOTT INTL INC NE Class A
Aug 5, 2019